Details of the management of the five PwHA undergoing arthroplasty
| . | Knee arthroplasty (participant A) . | Hip arthroplasty24 (participant B) . | Ankle arthroplasty (participant C) . | Hip arthroplasty (participant D) . | Hip arthroplasty (participant E) . | |
|---|---|---|---|---|---|---|
| Type of prophylaxis | rFVIIa | rFVIIa | pdFVIII | SHL FVIII | EHL FVIII | rFVIIa |
| Cumulative dose | ||||||
| Preoperative | 357.7 μg/kg | 98.4 μg/kg | — | 65.9 IU/kg | 78.6 IU/kg | 89.7 μg/kg |
| Postprocedure | 7064.1 μg/kg | 3688.5 μg/kg | 751.4 IU/kg | 395.6 IU/kg | 864.3 IU/kg | 4756.4 μg/kg |
| Doses in the first 7 d postprocedure | 48 | 11 | 5 | 11 | 22 | 33 |
| Total post-op days on prophylaxis or treatment | 29 | 17 | 7 | 19 | 16 | 23 |
| Bleed because of surgery | No | Yes | No | No | No | |
| Additional medication | Antifibrinolytic | SHL FVIII; antifibrinolytic∗ | — | — | Antifibrinolytic | |
| AEs of special interest | No TE or TMA | No TE or TMA | No TE or TMA | No TE or TMA | No TE or TMA | |
| . | Knee arthroplasty (participant A) . | Hip arthroplasty24 (participant B) . | Ankle arthroplasty (participant C) . | Hip arthroplasty (participant D) . | Hip arthroplasty (participant E) . | |
|---|---|---|---|---|---|---|
| Type of prophylaxis | rFVIIa | rFVIIa | pdFVIII | SHL FVIII | EHL FVIII | rFVIIa |
| Cumulative dose | ||||||
| Preoperative | 357.7 μg/kg | 98.4 μg/kg | — | 65.9 IU/kg | 78.6 IU/kg | 89.7 μg/kg |
| Postprocedure | 7064.1 μg/kg | 3688.5 μg/kg | 751.4 IU/kg | 395.6 IU/kg | 864.3 IU/kg | 4756.4 μg/kg |
| Doses in the first 7 d postprocedure | 48 | 11 | 5 | 11 | 22 | 33 |
| Total post-op days on prophylaxis or treatment | 29 | 17 | 7 | 19 | 16 | 23 |
| Bleed because of surgery | No | Yes | No | No | No | |
| Additional medication | Antifibrinolytic | SHL FVIII; antifibrinolytic∗ | — | — | Antifibrinolytic | |
| AEs of special interest | No TE or TMA | No TE or TMA | No TE or TMA | No TE or TMA | No TE or TMA | |
AE, adverse event; pdFVIII, plasma-derived factor VIII; post-op, post-operative; TE, thromboembolic event; TMA, thrombotic microangiopathy.
Recorded as an untreated bleed; however, upon further investigation, this bleed was managed with factor concentrate.